Torri D. Metz

Torri D. Metz

Auto-generated profile, based on publicly available information

Torri D. Metz

Obstetrics and Gynecology and Maternal-Fetal Medicine, University of Utah, Salt Lake City, UT

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2021 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
TMTorri D. Metz
Torri D. Metz
RCRebecca G. Clifton
Rebecca G. Clifton
BHBrenna L. Hughes
Brenna L. Hughes
GSGrecio Ma Sandoval
Grecio Ma Sandoval
GSGeorge R. Saade
George R. Saade
FNfor the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network
for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network
OBJECTIVE: To describe coronavirus disease 2019 (COVID-19) severity in pregnant patients and evaluate the association between disease severity and perinatal outcomes. METHODS: We conducted an observational cohort study of all pregnant patients with a singleton gestation and a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who delivered at 1 of 33 U.S. hospitals in 14 states from March 1 to July 31, 2020. Disease severity was classified by National Institutes of Health criteria. Maternal, fetal, and neonatal outcomes were abstracted by centrally trained and certified perinatal research staff. We evaluated trends in maternal characteristics and outcomes across COVID-19 severity classes and associations between severity and outcomes by multivariable modeling. RESULTS: A total of 1,219 patients were included: 47% asymptomatic, 27% mild, 14% moderate, 8% severe, 4% critical. Overall, 53% were Hispanic; there was no trend in race–ethnicity distribution by disease severity. Those with more severe illness had older mean age, higher median body mass index, and pre-existing medical comorbidities. Four maternal deaths (0.3%) were attributed to COVID-19. Frequency of perinatal death or a positive neonatal SARS-CoV-2 test result did not differ by severity. Adverse perinatal outcomes were more frequent among patients with more severe illness, including 6% (95% CI 2–11%) incidence of venous thromboembolism among those with severe–critical illness compared with 0.2% in mild–moderate and 0% in asymptomatic (P<.001 for trend across severity). In adjusted analyses, severe–critical COVID-19 was associated with increased risk of cesarean birth (59.6% vs 34.0%, adjusted relative risk [aRR] 1.57, 95% CI 1.30–1.90), hypertensive disorders of pregnancy (40.4% vs 18.8%, aRR 1.61, 95% CI 1.18–2.20), and preterm birth (41.8% vs 11.9%, aRR 3.53, 95% CI 2.42–5.14) compared with asymptomatic patients. Mild–moderate COVID-19 was not associated with adverse perinatal outcomes compared with asymptomatic patients. CONCLUSION: Compared with pregnant patients with SARS-CoV-2 infection without symptoms, those with severe–critical COVID-19, but not those with mild–moderate COVID-19, were at increased risk of perinatal complications.

7 February 2022 in JAMA
Verified
Journal Article
Open access
PDF file
TMTorri D. Metz
Torri D. Metz
RCRebecca G. Clifton
Rebecca G. Clifton
BHBrenna L. Hughes
Brenna L. Hughes
GSGrecio J. Sandoval
Grecio J. Sandoval
WGWilliam A. Grobman
William A. Grobman
HNHuman Development Maternal-Fetal Medicine Units (MFMU) Network
Human Development Maternal-Fetal Medicine Units (MFMU) Network
Pregnant individuals with COVID-19 are at increased risk of intensive care unit (ICU) admission, mechanical ventilation, and death compared with both pregnant individuals without SARS-CoV-2 infection and nonpregnant adults with SARS-CoV-2 infection.1-3 While COVID-19 increases the risk of maternal morbidity related to the virus (eg, as a result of severe acute respiratory syndrome), it remains unknown whether pregnant individuals with SARS-CoV-2 infection experience higher risk of serious morbidity from obstetric complications.

1 June 2018 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
BDBetsy Dickson
Betsy Dickson
CMChanel Mansfield
Chanel Mansfield
MGMaryam Guiahi
Maryam Guiahi
AAAmanda A. Allshouse
Amanda A. Allshouse
LBLaura M. Borgelt
Laura M. Borgelt
TMTorri D. Metz
Torri D. Metz
OBJECTIVE: To characterize recommendations given to pregnant women by Colorado cannabis dispensaries regarding use of cannabis products for nausea during the first trimester of pregnancy. METHODS: This was a statewide cross-sectional study in which advice about cannabis product use was requested using a mystery caller approach. The caller stated she was 8 weeks pregnant and experiencing morning sickness. Dispensaries were randomly selected from the Colorado Department of Revenue Enforcement Division website. The primary outcome was the proportion of marijuana dispensaries that recommended a cannabis product for use during pregnancy. We hypothesized that 50% of dispensaries would recommend use. A sample size of 400 was targeted to yield a two-sided 95% CI width of 10%. Secondary outcomes included the proportion endorsing cannabis use as safe during pregnancy, specific product recommendations, and encouraging discussion with a health care provider. Recommendations were compared by licensure type (medical, retail, or both) and location (rural vs urban). RESULTS: Of the 400 dispensaries contacted, 37% were licensed for medical sale (n=148), 28% for retail (n=111), and 35% for both (n=141). The majority, 69% (277/400), recommended treatment of morning sickness with cannabis products (95% CI 64–74%). Frequency of recommendations differed by license type (medical 83.1%, retail 60.4%, both 61.7%, P <.001). Recommendations for use were similar for dispensary location (urban 71% vs nonurban 63%, P =.18). The majority (65%) based their recommendation for use in pregnancy on personal opinion and 36% stated cannabis use is safe in pregnancy. Ultimately, 81.5% of dispensaries recommended discussion with a health care provider; however, only 31.8% made this recommendation without prompting. CONCLUSION: Nearly 70% of Colorado cannabis dispensaries contacted recommended cannabis products to treat nausea in the first trimester. Few dispensaries encouraged discussion with a health care provider without prompting. As cannabis legalization expands, policy and education efforts should involve dispensaries.

1 December 2015 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
TMTorri D. Metz
Torri D. Metz
ESElaine H. Stickrath
Elaine H. Stickrath

1 December 2016 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
TMTorri D. Metz
Torri D. Metz
PRPolina Rovner
Polina Rovner
MHM. Camille Md Hoffman
M. Camille Md Hoffman
AAAmanda A. Allshouse
Amanda A. Allshouse
KBKrista M. Msph Beckwith
Krista M. Msph Beckwith
IBIngrid A. Binswanger
Ingrid A. Binswanger
OBJECTIVE: To ascertain demographic and clinical characteristics of maternal deaths from self-harm (accidental overdose or suicide) to identify opportunities for prevention. METHODS: We report a case series of pregnancy-associated deaths resulting from self-harm in the state of Colorado between 2004 and 2012. Self-harm deaths were identified from several sources, including death certificates. Birth and death certificates along with coroner, prenatal care, and delivery hospitalization records were abstracted. Descriptive analyses were performed. For context, we describe demographic characteristics of women with a maternal death from self-harm and all women with live births in Colorado. RESULTS: Among the 211 total maternal deaths in Colorado over the study interval, 30% (n=63) resulted from self-harm. The pregnancy-associated death ratio from overdose was 5.0 (95% confidence interval [CI] 3.4–7.2) per 100,000 live births and from suicide 4.6 (95% CI 3.0–6.6) per 100,000 live births. Detailed records were obtained for 94% (n=59) of women with deaths from self-harm. Deaths were equally distributed throughout the first postpartum year (mean 6.21±3.3 months postpartum) with only six maternal deaths during pregnancy. Seventeen percent (n=10) had a known substance use disorder. Prior psychiatric diagnoses were documented in 54% (n=32) and prior suicide attempts in 10% (n=6). Although half (n=27) of the women with deaths from self-harm were noted to be taking psychopharmacotherapy at conception, 48% of them discontinued the medications during pregnancy. Fifty women had toxicology testing available; pharmaceutical opioids were the most common drug identified (n=21). CONCLUSION: Self-harm was the most common cause of pregnancy-associated mortality, with most deaths occurring in the postpartum period. A four-pronged educational and program building effort to include women, health care providers, health care systems, and both governments and organizations at the community and national levels may allow for a reduction in maternal deaths.

1 October 2017 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
TMTorri D. Metz
Torri D. Metz
AAAmanda A. Allshouse
Amanda A. Allshouse
CHCarol J. Hogue
Carol J. Hogue
RGRobert L. Goldenberg
Robert L. Goldenberg
DDDonald J. Dudley
Donald J. Dudley
RSRobert M. Silver
Robert M. Silver